MUSK and myasthenia gravis: In conclusion, N‐a represents a significant advancement in generalized MG (gMG) treatment, providing a targeted, effective, and well‐tolerated option that addresses a key unmet need for patients with acetylcholine receptor (AChR) or muscle‐specific kinase (MuSK) antibody‐positive disease.